Literature DB >> 29845408

Is there a role for immunotherapy in malignant pleural mesothelioma?

Alfredo Tartarone1, Rosa Lerose2, Michele Aieta3.   

Abstract

Malignant pleural mesothelioma (MPM) is a very aggressive malignancy, mainly caused by asbestos exposure. Patients with MPM have a poor prognosis that remained substantially unchanged in the last few years and limited effective therapeutic options with no recognized second or further-line therapy. In this context, also in view of the positive results observed in other tumor types, immunotherapy could play a relevant role. This review focuses on the most promising immunotherapies being investigated in MPM.

Entities:  

Keywords:  CAR T cell therapy; Immune checkpoint inhibitors; Immunotherapy; Malignant pleural mesothelioma

Mesh：

Substances：

Year:  2018        PMID： 29845408     DOI： 10.1007/s12032-018-1156-x

Source DB:  PubMed          Journal:  Med Oncol        ISSN： 1357-0560            Impact factor:   3.064


  26 in total

Review 1.  Review of malignant pleural mesothelioma survival after talc pleurodesis or surgery.

Authors:  Emanuela Taioli; Maaike van Gerwen; Meredith Mihalopoulos; Gil Moskowitz; Bian Liu; Raja Flores
Journal:  J Thorac Dis       Date:  2017-12       Impact factor: 2.895

2.  Malignant pleural mesothelioma: a population-based study of survival.

Authors:  Michael T Milano; Hong Zhang
Journal:  J Thorac Oncol       Date:  2010-11       Impact factor: 15.609

3.  Efficacy and safety of an intensified schedule of tremelimumab for chemotherapy-resistant malignant mesothelioma: an open-label, single-arm, phase 2 study.

Authors:  Luana Calabrò; Aldo Morra; Ester Fonsatti; Ornella Cutaia; Carolina Fazio; Diego Annesi; Marica Lenoci; Giovanni Amato; Riccardo Danielli; Maresa Altomonte; Diana Giannarelli; Anna Maria Di Giacomo; Michele Maio
Journal:  Lancet Respir Med       Date:  2015-03-26       Impact factor: 30.700

4.  CAR T-cell immunotherapy of MET-expressing malignant mesothelioma.

Authors:  Thivyan Thayaparan; Roseanna M Petrovic; Daniela Y Achkova; Tomasz Zabinski; David M Davies; Astero Klampatsa; Ana C Parente-Pereira; Lynsey M Whilding; Sjoukje Jc van der Stegen; Natalie Woodman; Michael Sheaff; Jennifer R Cochran; James F Spicer; John Maher
Journal:  Oncoimmunology       Date:  2017-08-14       Impact factor: 8.110

Review 5.  The blockade of immune checkpoints in cancer immunotherapy.

Authors:  Drew M Pardoll
Journal:  Nat Rev Cancer       Date:  2012-03-22       Impact factor: 60.716

6.  Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial.

Authors:  Gérard Zalcman; Julien Mazieres; Jacques Margery; Laurent Greillier; Clarisse Audigier-Valette; Denis Moro-Sibilot; Olivier Molinier; Romain Corre; Isabelle Monnet; Valérie Gounant; Frédéric Rivière; Henri Janicot; Radj Gervais; Chrystèle Locher; Bernard Milleron; Quan Tran; Marie-Paule Lebitasy; Franck Morin; Christian Creveuil; Jean-Jacques Parienti; Arnaud Scherpereel
Journal:  Lancet       Date:  2015-12-21       Impact factor: 79.321

Review 7.  Novel therapies for malignant pleural mesothelioma.

Authors:  Arnaud Scherpereel; Frederic Wallyn; Steven M Albelda; Camille Munck
Journal:  Lancet Oncol       Date:  2018-03       Impact factor: 41.316

8.  Molecular and Histopathological Characterization of the Tumor Immune Microenvironment in Advanced Stage of Malignant Pleural Mesothelioma.

Authors:  Namrata S Patil; Luisella Righi; Hartmut Koeppen; Wei Zou; Stefania Izzo; Federica Grosso; Roberta Libener; Marco Loiacono; Valentina Monica; Consuelo Buttigliero; Silvia Novello; Priti S Hegde; Mauro Papotti; Marcin Kowanetz; Giorgio V Scagliotti
Journal:  J Thorac Oncol       Date:  2017-10-24       Impact factor: 15.609

9.  Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial.

Authors:  Luana Calabrò; Aldo Morra; Ester Fonsatti; Ornella Cutaia; Giovanni Amato; Diana Giannarelli; Anna Maria Di Giacomo; Riccardo Danielli; Maresa Altomonte; Luciano Mutti; Michele Maio
Journal:  Lancet Oncol       Date:  2013-09-11       Impact factor: 41.316

Review 10.  Amatuximab and novel agents targeting mesothelin for solid tumors.

Authors:  Paolo Baldo; Sara Cecco
Journal:  Onco Targets Ther       Date:  2017-11-08       Impact factor: 4.147
View more
  2 in total

1.  Comprehensive Molecular and Pathologic Evaluation of Transitional Mesothelioma Assisted by Deep Learning Approach: A Multi-Institutional Study of the International Mesothelioma Panel from the MESOPATH Reference Center.

Authors:  Francoise Galateau Salle; Nolwenn Le Stang; Franck Tirode; Pierre Courtiol; Andrew G Nicholson; Ming-Sound Tsao; Henry D Tazelaar; Andrew Churg; Sanja Dacic; Victor Roggli; Daniel Pissaloux; Charles Maussion; Matahi Moarii; Mary Beth Beasley; Hugues Begueret; David B Chapel; Marie Christine Copin; Allen R Gibbs; Sonja Klebe; Sylvie Lantuejoul; Kazuki Nabeshima; Jean-Michel Vignaud; Richard Attanoos; Luka Brcic; Frederique Capron; Lucian R Chirieac; Francesca Damiola; Ruth Sequeiros; Aurélie Cazes; Diane Damotte; Armelle Foulet; Sophie Giusiano-Courcambeck; Kenzo Hiroshima; Veronique Hofman; Aliya N Husain; Keith Kerr; Alberto Marchevsky; Severine Paindavoine; Jean Michel Picquenot; Isabelle Rouquette; Christine Sagan; Jennifer Sauter; Francoise Thivolet; Marie Brevet; Philippe Rouvier; William D Travis; Gaetane Planchard; Birgit Weynand; Thomas Clozel; Gilles Wainrib; Lynnette Fernandez-Cuesta; Jean-Claude Pairon; Valerie Rusch; Nicolas Girard
Journal:  J Thorac Oncol       Date:  2020-03-09       Impact factor: 15.609

2.  Integrated analysis of DNA methylation and mRNA expression profiles to identify key genes in head and neck squamous cell carcinoma.

Authors:  Yu Jin; Xing Qin
Journal:  Biosci Rep       Date:  2020-01-31       Impact factor: 3.840
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.